Blood Test May Predict Future Cognitive Decline in Preclinical AD

Plasma p-tau217 can help identify amyloid-beta–positive individuals with preclinical Alzheimer's disease who are most likely to deteriorate in the coming years, new research suggests.
Medscape Medical News

source https://www.medscape.com/viewarticle/987960?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?